Carnosol

Carnosol is a potent Ribosomal S6 Kinase (RSK2) inhibitor that could be useful for treating gastric cancer, with an IC50 of ~5.5 μM[1]. Carnosol, a Nrf2 activator, increases the nuclear levels of Nrf2 and can promote the expression of heme oxygenase 1 (HMOX1) [2][3].

Product Specifications

CAS Number

[5957-80-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Endogenous Metabolite; Keap1-Nrf2; Ribosomal S6 Kinase (RSK)

Type

Natural Products

Related Pathways

MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Carnosol.html

Purity

99.90

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1O[C@]2([H])C3=C(C(O)=C(O)C(C(C)C)=C3)[C@@]41CCCC(C)(C)[C@]4([H])C2

Molecular Formula

C20H26O4

Molecular Weight

330.42

Precautions

H302, H315, H319, H335

References & Citations

[1]Wang L, et al. Carnosol suppresses patient-derived gastric tumor growth by targeting RSK2. Oncotarget. 2018 Feb 6;9 (76) :34200-34212.|[2]Li X, et al. Carnosol as a Nrf2 Activator Improves Endothelial Barrier Function Through Antioxidative Mechanisms. Int J Mol Sci. 2019;20 (4) :880. Published 2019 Feb 18.|[3]Martin D, et al. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem. 2004;279 (10) :8919-8929.